Scarica l'app Stockscreener
0.7101
0.17%
0.0012
Dopo l'orario di chiusura:
.71
-0.000100
-0.01%
Citius Oncology Inc Borsa (CTOR) Ultime notizie
CTOR Q1 2026 Earnings: Significant EPS Miss Signals Ongoing Development-Stage ChallengesEarnings Yield Analysis - dars.gov.et
Enterprise value to EBITDA forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
Price to sales forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
Citius Oncology, Inc. Actuals & Estimates (NASDAQ:CTOR) - TradingView
Citius Oncology, Inc. Actuals & Estimates (BOATS:CTOR) - TradingView
Price to earnings forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
Citius Oncology Inc (CTOR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Price to book forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
CTOR Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
CTOR Q1 2026 Earnings: Wider-Than-Expected Loss Alarms InvestorsEarnings Per Share - dars.gov.et
Citius Oncology Inc (CTOR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Citius Oncology Inc (CTOR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CITIUS ONCOLOGY INC (CTOR) Stock Chart - ChartMill
Citius Oncology Inc (CTOR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Citius Oncology Inc (CTOR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Citius Oncology Inc (CTOR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Citius Oncology Inc (CTOR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Citius Oncology Inc (CTOR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Citius Oncology Inc (CTOR) Institutional Confidence - TradingKey
CTOR Q1 2026 Earnings: Deep EPS Miss Highlights Pre‑Revenue ChallengesEstimate Revision Count - newsline.com
Citius Oncology Inc. (CTOR) Gains 6% as Buyers Defend Key SupportSentiment Divergence - newsline.com
CTOR Q1 2026 Earnings: Significant EPS Miss Highlights Continued Investment in PipelineRevenue Surprise History - newsline.com
Citius Oncology (CTOR) Edges Higher as Stock Hovers Near SupportMcClellan Summation - newsline.com
CTXR News | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
[EFFECT] CITIUS ONCOLOGY, INC. SEC Filing - Stock Titan
Citius Oncology (CTOR) stake updated by majority holder Citius Pharma - Stock Titan
Citius Oncology, Inc. Financial Disclosures & SEC Filings - TradingView
[EFFECT] Citius Pharmaceuticals, Inc. SEC Filing - Stock Titan
Citius Oncology Reports Promising Phase 1 Results for LYMPHIR Plus Pembrolizumab in Recurrent Gynecologic Cancers at ASCO 2026 123 - Minichart
Citius Oncology Highlights Promising Phase 1 Results for LYMPHIR® Plus Pembrolizumab in Recurrent Gynecologic Cancers at ASCO 2026 123 - Minichart
Citius Highlights LYMPHIR Combo Data in Gynecologic Cancers - TipRanks
Citius Oncology (CTOR) registers 6.8M warrant shares; highlights Phase 1 LYMPHIR data - Stock Titan
Citius Oncology (NASDAQ: CTOR) highlights Phase 1 LYMPHIR plus pembrolizumab results - Stock Titan
Citius Oncology Highlights Phase 1 Data in an Investigator-Initi - GuruFocus
Citius Oncology (CTXR) Presents Promising Data on LYMPHIR for Gy - GuruFocus
Citius Oncology presents study data on LYMPHIR combination By Investing.com - Investing.com Australia
Citius Oncology presents study data on LYMPHIR combination - Investing.com
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies - PR Newswire
Citius Oncology (NASDAQ: CTOR) clears potential $25M loan conversions and large warrants - Stock Titan
Citius Oncology (Nasdaq: CTOR) registers 32.9M shares tied to warrants and loan conversion - Stock Titan
CTOR Q1 2026 Earnings: Significant EPS Miss Amid Pre-Revenue PhaseBook Value Growth - thelegaladvocate.com
Number of shareholders of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combi - GuruFocus
Citius Oncology study combining LYMPHIR with pembrolizumab selected for ASCO presentation - Investing.com Nigeria
Citius Oncology study combining LYMPHIR with pembrolizumab selected for ASCO presentation By Investing.com - Investing.com South Africa
CTXRCitius Pharmaceuticals Inc Stock Price and Quote - Finviz
CTORCitius Oncology Inc Stock Price and Quote - Finviz
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting - PR Newswire
Citius Oncology Q1 2026 Earnings: Wide EPS Miss Highlights Pre-Revenue ChallengesManagement Guidance Update - newsline.com
Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts? - Yahoo Finance
CTOR Q1 2026 Earnings: Significant EPS Miss Amid Pre-Revenue StageNet Income Trends - The Legal Advocate
0.15%
1.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):